Real world data (RWD)—it’s a never-ending wave of information that is, increasingly, transforming healthcare into ‘reality medicine’ that responds to the real world use of medicines rather than that prescribed by randomised controlled trials (RCTs).
And because it’s so abundant, RWD is being mined everywhere, from the local country level to the ivory towers of academia. The result? Competitors, regulators and payers often know more about medicine usage than the companies that created them. In fact, pharma-generated RWD has influenced more than 25 percent of observed decisions relating to pricing and positioning.
How should pharma respond? In Strategies for Working with Real World Data, FirstWord makes a strong case for pharma-payer collaborations, as seen in the compelling work done between Merck and the Regenstrief Institute. Based on expert interviews, wide-ranging research and case studies, this report examines how the use of RWD is transforming the industry. It reveals what works—what doesn’t—and what pharma needs to do to stay ahead of the game.
Key Report Features of Strategies for Working with Real World Data include:
The supply and use of RWD is rapidly expanding. The pharmaceutical industry needs to grasp what is happening in ‘reality healthcare’ and with the competition. Through Strategies for Working with Real World Data, you will:
Strategies for Working with Real World Data answers key questions:
The pharmaceutical industry must keep abreast of how fast the supply and demand of RWD is occurring and be ready to apply key strategies to manage it. In this report, you will discover:
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved